This study is not yet open for patient recruitment.
Sponsored by M.D. Anderson Cancer Center
This is a Phase II trial to determine the effectiveness of 250 mg ZD1839 daily by mouth for 6 courses of treatment (1 course = 4 weeks) to determine its effectiveness on treating recurrent or metastatic squamous cell carcinoma of the skin.
Study ID Numbers: ID02-282
NLM Identifier: NCT00054691
COPYRIGHT 2003 Journal of Drugs in Dermatology
COPYRIGHT 2003 Gale Group